| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. | Cancer Prev Res (Phila) | 2011 | 1.57 |
| 2 | Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. | PLoS One | 2011 | 1.53 |
| 3 | Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. | PLoS One | 2013 | 0.80 |